Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

Recruiting Phase 1 Interventional Study
Gulf War Syndrome
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 – 70
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
80 (estimated)
Sponsor
Baylor College of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Gulf War Veterans of the U.S. military deployed on military orders to the Persian Gulf Region between August 2, 1990, and December 31, 1991 * Diagnosed with GWI according to the CDC and modified Kansas criteria as recommended by the Institute of Medicine (IOM), that is, endors…
Contacts

Jason K Aguilar, BA

713-440-4633

jason.aguilar@va.gov

CONTACT

Kandice Motley, BS

713-440-4445

kandice.motley@bcm.edu

CONTACT